Kasten, Inc. (OTC: KAST) announced today that it has completed a merger with Thru Pharma LLC dba DAKOTA Life Sciences. Upon review of Dakota during the phases of the JV setup, the Board of Directors and Members of Kasten and Dakota determined it was in the best interests of both entities and their stockholders, to consummate the merger of Kasten with and into Dakota with Kasten as the surviving entity. Read this in full along with more recent news for Kasten at: http://marketnewsupdates.com/news/kast.html
Dakota Life Sciences is engaged in developing innovative health products utilizing Site Specific Penetration Technology SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony™ OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies. Dakota Life Sciences is a leading anti-infectives private pharmaceutical Company, with award-winning products designed to provide the highest efficacy, for global patients at high risk of suffering from dangerous microbial and fungal infections.
“Dakota Life Sciences is the solution to take Kasten to the next level. They have a driven experienced management team and the product line already in place, to enhance shareholder value,” stated Jose Delgado, CEO of Kasten, Inc. “Dakota Life Sciences is very pleased to combine forces with Kasten,” said the President of Dakota Life Sciences, Steven Keough. “Our joint focus is to introduce a range of high efficacy affordable prescription and OTC pharmaceutical products that are unique to the market.”
In other industry related performance and recent announcements:
TG Therapeutics (NASDAQ: TGTX) closed up over 90% on Monday, at $10.20 trading over 33.5 Million shares by the market close. TG Therapeutics yesterday announced positive topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib, in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL). For the study, high risk was defined as having any one or more of the following: 17p deletion, 11q deletion or p53 mutation. The multicenter, randomized trial (NCT02301156), which assessed the efficacy and safety of TG-1101 plus ibrutinib, met its primary endpoint, demonstrating a statistically significant improvement in Overall Response Rate (ORR), compared to ibrutinib alone in both the Intent to Treat (ITT) population (p=0.001) and Treated population (p<0.001)
Xtant Medical Holdings, Inc. (NYSE: XTNT) closed up over 19% on Monday, at $0.61 trading over 1.5 Million shares by the market close – Xtant Medical Holdings announced last week that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on Thursday, March 9, 2017.
Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) closed up over 26% on Monday, at $1.77 trading over 7.2 Million shares by the market close. Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
Impax Laboratories, Inc. (NASDAQ: IPXL) closed up 5% on Monday, at $8.40 trading over 4.6 Million shares by the market close. Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, last week announced financial results for the fourth quarter and full year 2016 which can be seen at http://finance.yahoo.com/news/impax-reports-fourth-quarter-full-113500029.html
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Kasten, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact email: